<div id="readability-page-1"><div><p><span></span></p><ul><li>SANEGENEBIO ANNOUNCES RNAI GLOBAL LICENSING COLLABORATION WITH GENENTECH</li><li>SANEGENEBIO-WILL RECEIVE UPFRONT PAYMENT OF $200 MILLION, WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS OF UP TO $1.5 BILLION</li><li>SANEGENEBIO - GENENTECH WILL BE RESPONSIBLE FOR SUBSEQUENT CLINICAL DEVELOPMENT AND COMMERCIALIZATION GLOBALLY</li></ul></div></div>

<p>SANEGENEBIO ANNOUNCES RNAI GLOBAL LICENSING COLLABORATION WITH GENENTECHSANEGENEBIO-WILL RECEIVE UPFRONT PAYMENT OF $200 MILLION, WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS OF UP TO $1.5 BILLIONSANEGENEBIO - GENENTECH WILL BE RESPONSIBLE FOR SUBSEQUENT CLINICAL DEVELOPMENT AND COMMERCIALIZATION GLOBALLY</p>

Reuters

VanEck Biotech ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Proshares UltraShort Nasdaq Biotech

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Sanegenebio Announces Rnai Global Licensing Collaboration With Genentech